查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654165

糞鈣衛蛋白檢測市場規模、佔有率、趨勢分析報告：按分析、最終用途、地區和細分市場預測，2025-2030 年

Fecal Calprotectin Test Market Size, Share & Trends Analysis Report By Assay (Enzyme-linked Immunosorbent, Enzyme Fluroimmunoassay, Quantitative Immunochromatography), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

糞便鈣衛蛋白檢測市場的成長與趨勢

根據 Grand View Research, Inc. 的一份新報告，全球糞便鈣衛蛋白檢測市場規模預計到 2030 年將達到 95.5 億美元，2025-2030 年期間的複合年成長率為 11.2%。

大腸直腸癌是全球最常見的癌症之一，其發生率的增加是推動市場成長的主要因素。隨著醫療保健系統繼續優先考慮早期檢測以改善患者的治療效果並降低醫療保健成本，糞鈣衛蛋白檢測已成為識別消化道發炎的重要工具，可作為大腸癌的早期指標。該測試測量糞便檢體中的鈣衛蛋白水平，為醫療專業人員提供有價值的資訊，以確定是否需要進行大腸鏡檢查等進一步的診斷檢查。這種非侵入性方法比傳統診斷方法具有顯著優勢，使其成為患者和醫療保健提供者的首選。

推動糞鈣衛蛋白檢測市場成長的另一個關鍵因素是發炎性腸道疾病（包括克隆氏症和潰瘍性大腸炎）的盛行率不斷上升。這些慢性疾病會導致消化道炎症，需要持續監測和管理。糞鈣衛蛋白檢測在評估 IBD 患者的疾病活動性和監測治療反應中起著重要作用。隨著全球 IBD 盛行率的上升，對糞鈣衛蛋白檢測等可靠的非侵入性診斷工具的需求預計將會增加，尤其是在已開發國家。無需侵入性手術即可監測病情進展或復發，這是推動醫療保健提供者和患者採用該測試的關鍵優勢。

對預防性醫療保健重要性的認知不斷提高也是推動市場發展的關鍵因素。政府、醫療和倡導團體越來越重視大腸直腸癌和其他消化系統疾病的早期發現。許多國家都實施了結直腸癌國家篩檢計劃，糞便鈣衛蛋白檢測通常作為這些計劃的一部分。隨著越來越多的人接受定期篩檢，對糞便鈣衛蛋白檢測的需求預計會增加。此外，隨著大眾越來越意識到大腸直腸癌和 IBD 相關風險，對能夠在早期檢測這些疾病的診斷測試的需求不斷增加，從而進一步推動市場成長。

糞便鈣衛蛋白檢測技術的進步也促進了市場的擴張。隨著更準確、更快速、更方便用戶使用的檢測設備的發展，糞鈣衛蛋白檢測變得更加便捷和高效。自動分析儀和家庭檢測套組等技術創新使得醫療保健提供者和患者更容易使用這種診斷工具。特別是自動化系統簡化了測試流程，提高了臨床實驗室的吞吐量並提高了測試效率。另一方面，家用檢測套組為患者提供了一種方便的方式，讓他們可以在舒適的家中監測自己的胃腸道健康。這些進展正在推動糞便鈣衛蛋白檢測的廣泛應用，特別是在醫療保健有限且患者更喜歡獨立管理健康的地區。

市場的主要參與企業正專注於技術進步，例如開發易於使用的自動化系統，以簡化測試流程並提高臨床照護端的處理能力。此外，家庭檢測解決方案的趨勢日益成長，像 BIOHIT Medical 這樣的公司推出了自我檢測套組，讓患者可以遠端監控自己的病情。隨著企業尋求擴大產品系列併加強其市場影響力，夥伴關係、聯盟和收購也在增加。在日益擁擠的市場中，各公司不斷努力使其產品與眾不同，競爭策略在很大程度上受到提高測試靈敏度、降低成本和增加患者便利性的需求的影響。

糞便鈣衛蛋白檢測市場報告重點

  • 根據檢測方法，酵素結合免疫吸附測定法在 2024 年佔據最大的收入佔有率，為 66.4%。其優越性的關鍵原因之一是其在準確檢測與發炎性腸道疾病腸道疾病（IBD）和大腸癌等胃腸道疾病相關的發炎方面具有高靈敏度和特異性。
  • 根據應用，發炎性腸道疾病將佔據市場主導地位，到 2024 年將佔據 66.0% 的最大佔有率。這是因為它在已開發國家和新興國家中都越來越流行。
  • 根據最終用途，醫院和診所佔比最大，到 2024 年將達到 54.7%。這一領域佔據主導地位，是因為醫院中接受檢測的患者數量龐大。
  • 由於擁有大量主要市場參與企業，北美在全球市場佔據主導地位。北美是腸躁症 (IBS) 和其他胃病的發生率較高的地區。此外，該地區完善的醫療基礎設施也有助於市場的發展。
  • 由於新興市場醫療設施的開放，亞太地區預計將以最快的速度成長，在 2025-2030 年的預測期內複合年成長率為 12.7%。此外，對預防性定期檢查的日益重視也推動了市場的成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 糞便鈣衛蛋白檢測市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 糞便鈣衛蛋白檢測市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析

第 4 章糞便鈣衛蛋白檢測市場分析、估計與趨勢分析

  • 2024 年及 2030 年檢測市場佔有率
  • 細分儀表板
  • 全球糞便鈣衛蛋白檢測市場前景（依檢測方法）
  • 2018-2030 年市場規模、預測及趨勢分析
    • 酵素免疫分析法
    • 螢光免疫分析
    • 定量層析法

第 5 章糞便鈣衛蛋白檢測市場：按應用進行的估計和趨勢分析

  • 2024 年和 2030 年應用市場佔有率
  • 細分儀表板
  • 全球糞便鈣衛蛋白檢測市場應用前景
  • 2018-2030 年市場規模、預測及趨勢分析
    • 發炎性腸道疾病
    • 大腸直腸癌
    • 其他

6. 糞便鈣衛蛋白檢測市場：依最終用途的估計和趨勢分析

  • 2024 年及 2030 年終端用途市場佔有率
  • 細分儀表板
  • 全球糞便鈣衛蛋白檢測市場前景（依最終用途）
  • 2018-2030 年市場規模、預測及趨勢分析
    • 醫院和診所
    • 診斷實驗室
    • 學術研究所

7. 糞便鈣衛蛋白檢測市場：區域、估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 2024 年主要企業的市場佔有率分析
    • Epitope Diagnostics Inc.
    • Hycult BIoTech
    • Actim
    • Eagle Biosciences, Inc.
    • OPERON
    • Svar Life Science
    • BUHLMANN
    • DRG International Inc.
    • ALPCO
    • Diazyme Laboratories
Product Code: GVR-4-68040-500-1

Fecal Calprotectin Test Market Growth & Trends:

The global fecal calprotectin test market size is expected to reach USD 9.55 billion by 2030, registering a CAGR of 11.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of colorectal cancer, which has become one of the most common forms of cancer worldwide, is the major factor for the market growth. As healthcare systems continue to prioritize early detection to improve patient outcomes and reduce healthcare costs, fecal calprotectin testing has emerged as an essential tool for identifying inflammation in the gastrointestinal tract, which can be an early indicator of colorectal cancer. The test, which measures the concentration of calprotectin in stool samples, provides healthcare professionals with valuable information to determine whether further diagnostic procedures, such as colonoscopies, are necessary. This non-invasive approach offers a significant advantage over traditional diagnostic methods, making it a preferred option for both patients and healthcare providers.

Another significant factor contributing to the growth of the fecal calprotectin test market is the increasing prevalence of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. These chronic conditions, which cause inflammation in the digestive tract, require ongoing monitoring and management. Fecal calprotectin tests plays a crucial role in assessing disease activity and monitoring treatment response in patients with IBD. As the global incidence of IBD rises, particularly in developed countries, the demand for reliable, non-invasive diagnostic tools like fecal calprotectin tests is expected to increase. The ability to monitor disease progression and flare-ups without the need for invasive procedures is a key advantage that is driving the adoption of this test among healthcare providers and patients.

The growing awareness of the importance of preventive healthcare is also a significant factor driving the market. Governments, healthcare organizations, and advocacy groups are increasingly focusing on the early detection of colorectal cancer and other gastrointestinal disorders. National screening programs for colorectal cancer are being implemented in many countries, and fecal calprotectin tests are often included as part of these programs. As more individuals undergo routine screening, the demand for fecal calprotectin test is expected to rise. Additionally, as the general population becomes more aware of the risks associated with colorectal cancer and IBD, there is a growing demand for diagnostic tests that can detect these conditions early, further fueling market growth.

Technological advancements in fecal calprotectin test is also contributing to the market's expansion. The development of more accurate, faster, and user-friendly testing devices has made fecal calprotectin tests more accessible and efficient. Innovations such as automated analyzers and home testing kits have made it easier for both healthcare providers and patients to use this diagnostic tool. Automated systems, in particular, have streamlined the testing process, allowing for higher throughput in clinical laboratories and improving the efficiency of testing. Home test kits, on the other hand, provide patients with a convenient way to monitor their gastrointestinal health in the comfort of their own homes. These advancements are helping to drive the adoption of fecal calprotectin tests, particularly in regions where healthcare access may be limited or where patients prefer to manage their health independently.

Key players in the market are focusing on technological advancements, such as the development of user-friendly, automated systems that streamline the testing process and improve throughput in clinical settings. Additionally, there is a growing trend toward home-based testing solutions, with companies like BIOHIT Healthcare introducing self-test kits that allow patients to monitor their condition remotely. The market is also witnessing an increase in partnerships, collaborations, and acquisitions as companies seek to expand their product portfolios and strengthen their market presence. Competitive strategies are heavily influenced by the need to improve test sensitivity, reduce costs, and enhance patient convenience, with companies continuously working to differentiate their products in an increasingly crowded market.

Fecal Calprotectin Test Market Report Highlights:

  • Based on assay, enzyme-linked immunosorbent assay accounted for the largest revenue share of 66.4% in 2024. One of the primary reasons for its dominance is its high sensitivity and specificity, which allows for accurate detection of inflammation associated with gastrointestinal disorders such as inflammatory bowel diseases (IBD) and colorectal cancer
  • Based on application, inflammatory bowel disease dominated the market and accounted for the largest share of 66.0% in 2024.This can be attributed to the increasing prevalence of the disease in emerging as well as developed nations
  • Based on end-use, the hospitals and clinics segment dominated the end use segments with the largest market share of 54.7% in 2024. The segment dominance is attributed to large patient volumes being tested in hospitals
  • North America dominated the global market due to the presence of a large number of major market players. North America has a high prevalence of IBS and other gastric diseases. Furthermore, well-developed healthcare infrastructure fuels regional market growth
  • Asia Pacific is expected to witness the fastest growth with a CAGR of 12.7% over the forecast period from 2025 to 2030, due to the development of healthcare facilities across emerging markets. Furthermore, increasing focus on preventive routine testing is also supporting the market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Assay
    • 1.2.2. Application
    • 1.2.3. End-use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Assay outlook
    • 2.2.2. Application outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Fecal Calprotectin Test Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Colorectal Cancer and IBD
      • 3.2.1.2. Growing Focus on Preventive Healthcare
      • 3.2.1.3. Growing demand for Non-invasive Testing
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited Awareness in Some Regions
      • 3.2.2.2. High Cost of Testing in Certain Markets
  • 3.3. Fecal Calprotectin Test Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Fecal Calprotectin Test Market: Assay Estimates & Trend Analysis

  • 4.1. Assay Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Fecal Calprotectin Test Market by Assay Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Enzyme-Linked Immunosorbent Assay
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.2. Enzyme Fluroimmunoassay
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Quantitative Immunochromatography
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Fecal Calprotectin Test Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Fecal Calprotectin Test Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Inflammatory Bowel Disease
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.2. Colorectal Cancer
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Others
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Fecal Calprotectin Test Market: End-Use Estimates & Trend Analysis

  • 6.1. End-Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Fecal Calprotectin Test Market by End-Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals and Clinics
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Diagnostic Laboratories
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Academic and Research Institutes
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Fecal Calprotectin Test Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Target disease prevalence
      • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Target disease prevalence
      • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Target disease prevalence
      • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Target disease prevalence
      • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Target disease prevalence
      • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Target disease prevalence
      • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Target disease prevalence
      • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Target disease prevalence
      • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Target disease prevalence
      • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. Target disease prevalence
      • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Target disease prevalence
      • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Target disease prevalence
      • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Target disease prevalence
      • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company market share analysis, 2024
    • 8.3.2. Epitope Diagnostics Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Hycult Biotech
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Actim
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Eagle Biosciences, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. OPERON
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Svar Life Science
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. BUHLMANN
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. DRG International Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. ALPCO
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Diazyme Laboratories
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table. 1 List of Abbreviation
  • Table. 2 North America Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 3 North America Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 4 North America Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 5 North America Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 6 U.S. Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 7 U.S. Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 8 U.S. Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 9 Canada Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 10 Canada Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 11 Canada Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 12 Mexico Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 13 Mexico Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 14 Mexico Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 15 Europe Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 16 Europe Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 17 Europe Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 18 Europe Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 19 Germany Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 20 Germany Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 21 Germany Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 22 UK Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 23 UK Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 24 UK Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 25 France Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 26 France Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 27 France Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 28 Italy Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 29 Italy Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 30 Italy Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 31 Spain Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 32 Spain Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 33 Spain Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 34 Sweden Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 35 Sweden Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 36 Sweden Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 37 Norway Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 38 Norway Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 39 Norway Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 40 Denmark Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 41 Denmark Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 42 Denmark Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 43 Asia Pacific Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 44 Asia Pacific Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 45 Asia Pacific Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 46 Asia Pacific Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 47 China Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 48 China Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 49 China Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 50 Japan Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 51 Japan Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 52 Japan Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 53 India Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 54 India Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 55 India Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 56 Australia Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 57 Australia Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 58 Australia Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 59 Thailand Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 60 Thailand Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 61 Thailand Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 62 South Korea Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 63 South Korea Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 64 South Korea Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 65 Latin America Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 66 Latin America Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 67 Latin America Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 68 Latin America Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 69 Brazil Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 70 Brazil Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 71 Brazil Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 72 Argentina Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 73 Argentina Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 74 Argentina Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 75 Middle East and Africa Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 76 Middle East and Africa Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 77 Middle East and Africa Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 78 Middle East and Africa Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
  • Table. 79 South Africa Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 80 South Africa Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 81 South Africa Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 82 Saudi Arabia Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 83 Saudi Arabia Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 84 Saudi Arabia Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 85 UAE Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 86 UAE Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 87 UAE Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
  • Table. 88 Kuwait Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
  • Table. 89 Kuwait Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
  • Table. 90 Kuwait Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Fecal Calprotectin Test: Market outlook
  • Fig. 9 Fecal Calprotectin Test: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Fecal Calprotectin Test Market driver impact
  • Fig. 15 Fecal Calprotectin Test Market restraint impact
  • Fig. 16 Fecal Calprotectin Test Market strategic initiatives analysis
  • Fig. 17 Fecal Calprotectin Test market: Assay movement analysis
  • Fig. 18 Fecal Calprotectin Test market: Assay outlook and key takeaways
  • Fig. 19 Enzyme-Linked Immunosorbent Assay market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Enzyme Fluroimmunoassay market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Quantitative Immunochromatography market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Fecal Calprotectin Test market: Application movement analysis
  • Fig. 23 Fecal Calprotectin Test market: Application outlook and key takeaways
  • Fig. 24 Inflammatory Bowel Disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Fecal Calprotectin Test market: End-Use movement analysis
  • Fig. 28 Fecal Calprotectin Test market: End-Use outlook and key takeaways
  • Fig. 29 Hospitals and Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Academic and Research Institutes market estimates and forecasts, 2018 - 2030
  • Fig. 32 Global Fecal Calprotectin Test market: Regional movement analysis
  • Fig. 33 Global Fecal Calprotectin Test market: Regional outlook and key takeaways
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.K. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)